Moreover, intersection of our identified GRHL2 peaks with published ER⍺ binding events in the same series of luminal breast cancer cells cultured under the same conditions further indicates that GRHL2 binds most of the targets found by us in absence of ER⍺, FOXA1, and GATA3. This evidence concerns the gene GRHL2 and breast carcinoma.